Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium

Shanly C. Seferina, Bram L. T. Ramaekers, Maaike de Boer, M. Wouter Dercksen, Franchette van den Berkmortel, Roel J. W. van Kampen, Agnes J. van de Wouw, Adri C. Voogd, Vivianne C. G. Tjan Heijnen, Manuela A. Joore*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)79223-79233
Number of pages11
JournalOncotarget
Volume8
Issue number45
DOIs
Publication statusPublished - 3 Oct 2017

Keywords

  • trastuzumab
  • cost-effectiveness
  • early breast cancer
  • real-world
  • Markov model
  • RANDOMIZED CONTROLLED-TRIAL
  • ECONOMIC EVALUATIONS
  • MODEL
  • CHEMOTHERAPY
  • THERAPY
  • IMPACT
  • HERA

Cite this